P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 20.93 CNY -0.05% Market Closed
Market Cap: 15.3B CNY
Have any thoughts about
Pacific Shuanglin Bio pharmacy Co Ltd?
Write Note

Pacific Shuanglin Bio pharmacy Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pacific Shuanglin Bio pharmacy Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Total Liabilities & Equity
ÂĄ8.8B
CAGR 3-Years
9%
CAGR 5-Years
47%
CAGR 10-Years
21%
Beigene Ltd
HKEX:6160
Total Liabilities & Equity
ÂĄ41.1B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Liabilities & Equity
ÂĄ20.3B
CAGR 3-Years
7%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities & Equity
ÂĄ15.7B
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities & Equity
ÂĄ54.8B
CAGR 3-Years
26%
CAGR 5-Years
38%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities & Equity
ÂĄ6.9B
CAGR 3-Years
14%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
15.3B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Intrinsic Value
33.41 CNY
Undervaluation 37%
Intrinsic Value
Price
P

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
8.8B CNY

Based on the financial report for Sep 30, 2024, Pacific Shuanglin Bio pharmacy Co Ltd's Total Liabilities & Equity amounts to 8.8B CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
21%

Over the last year, the Total Liabilities & Equity growth was 7%. The average annual Total Liabilities & Equity growth rates for Pacific Shuanglin Bio pharmacy Co Ltd have been 9% over the past three years , 47% over the past five years , and 21% over the past ten years .

Back to Top